Tavexia Lifecare: ₹67.19 Cr Meyonex Deal (2026)

What the board approved and why it matters

Tavexia Lifecare has secured approval to acquire a 60% controlling equity stake in Meyonex Pharmaceuticals. The company’s board of directors approved the transaction at its meeting held on October 7, 2026. The proposed investment is valued at ₹67.19 crore and is structured as a cash subscription to new shares, not a purchase from existing shareholders. The company has positioned the move as a shift towards pharmaceutical manufacturing, formulations and CDMO services. Tavexia Lifecare has historically been associated with burner manufacturing and trading operations, and the acquisition signals a planned expansion into pharmaceuticals and wellness.

Deal structure: fresh share subscription at ₹32 per share

The acquisition will be executed through subscription to 2,09,97,180 fresh equity shares of Meyonex Pharmaceuticals. The issue price has been set at ₹32 per share, and the payment mode is entirely cash. Based on the disclosed terms, the total consideration is ₹67.19 crore (₹67,19,09,760). Because the shares are newly issued, the transaction will expand Meyonex’s equity base. Tavexia Lifecare will become the majority shareholder upon allotment, subject to completion conditions.

Control outcome and post-allotment shareholding

After completion of the fresh issue and allotment, Tavexia Lifecare is expected to hold a controlling 60% stake in Meyonex Pharmaceuticals. Existing shareholders of Meyonex will retain the remaining 40% post-allotment. The total post-allotment paid-up equity share capital of Meyonex is disclosed to stand at 3,49,95,300 shares. The company has also stated that the acquisition is not related to promoter group companies. It has further clarified that the transaction does not constitute a slump sale.

Operational footprint: Tarapur manufacturing and commercial base

Tavexia Lifecare said the transaction provides an immediate operational foothold through Meyonex’s established manufacturing and commercial operations. These operations are situated at MIDC Tarapur in Maharashtra. The company described the acquisition as one that can deliver synergies and create an immediate growth runway, enabling it to scale its revenue baseline and leverage operational efficiencies. While such benefits are contingent on execution, the disclosed rationale centres on gaining operating infrastructure rather than building capacity from scratch.

Conditions, approvals, and how completion is expected to happen

The disclosed consideration is subject to execution of definitive agreements and fulfilment of applicable statutory and regulatory conditions. Tavexia Lifecare has indicated that shareholder approval will be required wherever applicable. Regulatory approvals remain pending as the company proceeds with definitive documentation. The company has also stated that the acquisition could be completed in one or more tranches. These conditions mean the board approval sets the framework, but closing will depend on further steps and approvals.

Funding plan: exploring equity or convertible instruments

Alongside the acquisition decision, Tavexia Lifecare has indicated it is exploring fresh fund-raising options to support the acquisition and expansion. The company has referred to strategic fund-raising via equity or convertible instruments. It has also indicated that funding could be planned through a future preferential issue or rights issue of securities. No detailed fund-raise size or timeline has been disclosed in the provided information. The financing plan matters because the subscription is all-cash and is tied to a fixed consideration.

Meyonex profile and recent financial performance disclosed

Meyonex Pharmaceuticals is described as an unlisted public company incorporated in India. The company was incorporated in 2015, according to the provided details. Meyonex reported a turnover of ₹13.32 crore in FY24 and ₹10.79 crore in FY25, showing a decline in the last reported financial year. These figures provide context on the scale of the target company relative to the proposed investment. They also help investors assess how quickly the acquisition could translate into consolidated revenue growth once control is obtained.

Market reaction and what investors typically track next

The headline event was followed by a rise in Tavexia Lifecare’s shares, as referenced in the source summary, although no percentage move is provided. Investors usually track three near-term milestones that are explicitly relevant here: completion of the share subscription, integration of the acquired operations, and clarity on the financing structure. For this transaction, the key swing factors are the timeline for regulatory and shareholder approvals and the execution of definitive agreements. The company’s October 12 disclosure is referenced as the basis for several deal specifics, including the Tarapur operating base.

Key deal facts at a glance

Turnover numbers disclosed for Meyonex

Conclusion

Tavexia Lifecare’s board-approved plan to subscribe ₹67.19 crore in cash for a 60% stake in Meyonex Pharmaceuticals is a clear step towards pharma manufacturing, formulations and CDMO services. The structure, share count, pricing, and post-deal ownership are defined, but completion remains subject to definitive documentation and pending approvals. The next confirmed milestones, based on the disclosures, are the execution of agreements, securing applicable statutory and regulatory clearances, and completing the share allotment, potentially in tranches.